|
|
| (10 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ticagrelor#Adult Indications and Dosage]] |
| {{Ticagrelor}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with [[acute coronary syndrome]] (ACS) ([[unstable angina]], non-ST elevation [[myocardial infarction]], or ST elevation [[myocardial infarction]]). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, [[myocardial infarction]] or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the rate of stent [[thrombosis]] [see Clinical Studies (14)].
| |
| | |
| BRILINTA has been studied in ACS in combination with [[aspirin]]. Maintenance doses of [[aspirin]] above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of [[aspirin]] above 100 mg daily [see Warnings and Precautions (5.2) and Clinical Studies (14)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| {{Antithrombotics}}
| |
| | |
| [[Category:ADP receptor inhibitors]]
| |
| [[Category:Triazolopyrimidines]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Alcohols]]
| |
| [[Category:AstraZeneca]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |